Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Past Issues
    • Accepted Articles
    • Email Alerts
    • RSS
    • Terms of Use
  • About PDA JPST
    • JPST Editors and Editorial Board
    • About/Vision/Mission
    • Paper of the Year
  • Author & Reviewer Resources
    • Author Resources / Submit
    • Reviewer Resources
  • JPST Access and Subscriptions
    • PDA Members
    • Institutional Subscriptions
    • Nonmember Access
  • Support
    • Join PDA
    • Contact
    • Feedback
    • Advertising
    • CiteTrack
  • .
    • Visit PDA
    • PDA Letter
    • Technical Reports
    • news uPDATe
    • Bookstore

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
PDA Journal of Pharmaceutical Science and Technology
  • .
    • Visit PDA
    • PDA Letter
    • Technical Reports
    • news uPDATe
    • Bookstore
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
PDA Journal of Pharmaceutical Science and Technology

Advanced Search

  • Home
  • Content
    • Current Issue
    • Past Issues
    • Accepted Articles
    • Email Alerts
    • RSS
    • Terms of Use
  • About PDA JPST
    • JPST Editors and Editorial Board
    • About/Vision/Mission
    • Paper of the Year
  • Author & Reviewer Resources
    • Author Resources / Submit
    • Reviewer Resources
  • JPST Access and Subscriptions
    • PDA Members
    • Institutional Subscriptions
    • Nonmember Access
  • Support
    • Join PDA
    • Contact
    • Feedback
    • Advertising
    • CiteTrack
  • Follow pda on Twitter
  • Visit PDA on LinkedIn
  • Visit pda on Facebook
Article CommentaryCommentary

Visible Particulate Contamination Control for Injectable Products: A Life-Cycle Approach

Stephen E. Langille
PDA Journal of Pharmaceutical Science and Technology May 2020, 74 (3) 359-366; DOI: https://doi.org/10.5731/pdajpst.2019.010462
Stephen E. Langille
ValSource, Inc., 918A Horseshoe Pike, Dowingtown, PA 19335
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
Loading

References

  1. 1.↵
    1. Woodcock J.
    The Concept of Pharmaceutical Quality. Am. Pharm. Rev. 2004, 7 (6), 1–3.
    OpenUrl
  2. 2.↵
    1. Langille S. E.
    Particulate Matter in Injectable Drug Products. PDA J. Pharm. Sci. Technol. 2013, 67 (3), 186–200.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    U.S. Pharmacopeial Convention, General Chapter <1> Injections and Implanted Drug Products (Parenterals) – Product Quality Tests. In USP 42–NF 37, USP: Rockville, MD, 2019.
  4. 4.↵
    Council of Europe. Parenteral Preparations, Monograph 0520. In European Pharmacopoeia (Ph. Eur.), 9th Edition, Council of Europe: Strasbourg, France, 2018.
  5. 5.↵
    Ministry of Health Labour and Welfare of Japan, General Tests, Process and Apparatus–6.06: Foreign Insoluble Matter Test for Injections. In The Japanese Pharmacopoeia, 17th Edition (English Version), MHLW: Tokyo, 2018.
  6. 6.↵
    U.S. Pharmacopeial Convention, General Chapter <790> Visible Particulates in Injections. In USP 42–NF 37, USP: Rockville, MD, 2019.
  7. 7.↵
    1. Wang H. S.
    Regulatory Perspective on Inspection of Injectable Products for Visible Particulates. Presented at PDA Visual Inspection Forum, Washington, DC, April 23, 2019.
  8. 8.↵
    1. Taylor P.
    Top 5 Reasons for a Class I Product Recall. Pharmafile [Online] 2011. http://www.pharmafile.com/news/154814/top-5-reasons-class-i-product-recall (accessed Aug 2, 2019).
  9. 9.↵
    Parenteral Drug Association Inc. Technical Report No. 79: Particulate Matter Control in Difficult to Inspect Parenterals; Bethesda, MD, 2018.
  10. 10.↵
    1. Aldrich D. S.,
    2. Cherris R. T.,
    3. Shabushnig J. G.
    Visual Inspection and Particulate Control, 1st ed; Davis Healthcare International Publishing, LLC: River Grove, IL, 2016; pp 231–307.
  11. 11.↵
    U.S. Pharmacopeial Convention, General Chapter <1790> Visible Inspection of Injections. In USP 41–NF 36, USP: Rockville, MD, 2018.
  12. 12.↵
    International Conference for Harmonisation, Quality Guideline Q8: Pharmaceutical Development. ICH Geneva, 2005.
  13. 13.↵
    U.S. Food and Drug Administration, Guidance for Industry: PAT–A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance. Center for Biologics Evaluation and Research. U.S. Department of Health and Human Services: Rockville, MD, 2004.
  14. 14.↵
    GMP Question and Answers. World Health Organization Web Site. https://www.who.int/medicines/areas/quality_safety/quality_assurance/gmp/en/ (accessed July 10, 2019).
  15. 15.↵
    U.S. Food and Drug Administration, Guidance for Industry: Quality Systems Approach to Pharmaceutical CGMP Regulations. Center for Biologics Evaluation and Research. U.S. Department of Health and Human Services: Rockville, MD, 2006.
  16. 16.↵
    U.S. Food and Drug Administration, Guidance for Industry: Process Validation: General Principles and Practices. Center for Biologics Evaluation and Research. U.S. Department of Health and Human Services: Rockville, MD, 2011.
  17. 17.↵
    European Medicines Agency, Guideline on the Sterilisation of the Medicinal Product, Active Substance, Excipient and Primary Container. EMA: London, 2019.
  18. 18.
    U.S. Food and Drug Administration, 21 CFR Part 211--Current Good Manufacturing Practice for Finished Pharmaceuticals. U.S. Department of Health and Human Services, Government Publishing Office: Washington, D.C., 2019.
  19. 19.
    Federal Food, Drug, and Cosmetic Act. U.S. Code, Sections 301-382, Title 21, 2019.
PreviousNext
Back to top

In This Issue

PDA Journal of Pharmaceutical Science and Technology: 74 (3)
PDA Journal of Pharmaceutical Science and Technology
Vol. 74, Issue 3
May/June 2020
  • Table of Contents
  • Index by Author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on PDA Journal of Pharmaceutical Science and Technology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Visible Particulate Contamination Control for Injectable Products: A Life-Cycle Approach
(Your Name) has sent you a message from PDA Journal of Pharmaceutical Science and Technology
(Your Name) thought you would like to see the PDA Journal of Pharmaceutical Science and Technology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
3 + 13 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Visible Particulate Contamination Control for Injectable Products: A Life-Cycle Approach
Stephen E. Langille
PDA Journal of Pharmaceutical Science and Technology May 2020, 74 (3) 359-366; DOI: 10.5731/pdajpst.2019.010462

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Visible Particulate Contamination Control for Injectable Products: A Life-Cycle Approach
Stephen E. Langille
PDA Journal of Pharmaceutical Science and Technology May 2020, 74 (3) 359-366; DOI: 10.5731/pdajpst.2019.010462
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Cost of Visible Particulate Contamination
    • Life-Cycle Approach to Visible Particulate Control
    • FDA Regulations and the Life-Cycle Approach
    • Summary
    • Conflict of Interest Declaration
    • References
  • Figures & Data
  • References
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Comparing visual inspection methods for parenteral products in hospital pharmacy: between reliability, cost, and operator formation considerations
  • Development and Qualification of Visible Particle Load Analysis Methods for Injectable Drug Product Primary Packaging Components
  • Google Scholar

More in this TOC Section

  • Challenges and Solutions to Manufacturing of Low-Viscosity, Ultra-High Concentration IgG1 Drug Products: From Late Downstream Process to Final Fill Finish Processing
  • Retrospective Evaluation of Cycled Resin in Viral Clearance Studies - A Multiple Company Collaboration - Post ICH Q5A(R2) Review
  • Addressing Medical Device Extractables and Leachables via Non-Target Analysis (NTA); The Analytical Evaluation Threshold (AET) and Quantitation
Show more Commentary

Similar Articles

Keywords

  • Particulate
  • Life cycle
  • Visible
  • Contamination
  • Injectable
  • control

Readers

  • About
  • Table of Content Alerts/Other Alerts
  • Subscriptions
  • Terms of Use
  • Contact Editors

Author/Reviewer Information

  • Author Resources
  • Submit Manuscript
  • Reviewers
  • Contact Editors

Parenteral Drug Association, Inc.

  • About
  • Advertising/Sponsorships
  • Events
  • PDA Bookstore
  • Press Releases

© 2025 PDA Journal of Pharmaceutical Science and Technology Print ISSN: 1079-7440  Digital ISSN: 1948-2124

Powered by HighWire